Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of dosing interval on immune-related adverse events and infusion reaction of nivolumab and pembrolizumab
jRCT1030230268Recruiting
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and pembrolizumab in Neoplasm (4 arms), sponsored by none. Primary endpoints: Incidence of immune-related adverse events by dosing interval for nivolumab and Incidence of immune-related adverse events by dosing interval for pembrolizumab. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
Neoplasm
Beyond the preview
Go deeper on jRCT1030230268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230268.